Intellectual Property

Everyone is talking about semaglutide and tirzepatide. The blockbuster revenues, the obesity boom , the  reshaping of pharma valuations. But while the commercial story dominates headlines, a quieter and  arguably more  consequential race is playing out in patent offices across the globe. The question  isn't  whether GLP-1 generics are coming.  It's  when, where, and through how many layers of IP  they'll  have to fight. Here's  what most market commentary misses: GLP-1 drugs  don't  sit behind a single patent wall. They carry layered protection including compound patents, formulation patents, delivery device patents, and method-of-use claims, each expiring independently, across different  jurisdictions , on different timelines. Clearing the diabetes IP  doesn't  automatically open the door to the obesity  indication .  That's  a separate and newer thicket, with filings that extend exclusivity well ...

  Most IP teams in 2026 have access to powerful patent monitoring tools. Hundreds of millions of filings, real-time alerts, multi- jurisdiction   coverage  the infrastructure is genuinely impressive. And yet, companies are still getting blindsided by competitor filings they should have caught. Licensing opportunities are  sitting  dormant in their own portfolios. Something  isn't   adding  up.   The problem  isn't   access to  data anymore.  It's  what happens after the alert lands in your inbox.   Alert fatigue is real, and  it's  quietly killing your monitoring program.  When your system pings you with dozens of marginally relevant notifications every week, the natural human response is to skim and move on.  The signal you actually needed gets buried.  Over time, your monitoring system becomes background noise rather than a decision-making tool.   The fix  isn't  more ale...

  Despite advances in Patent Search Software and AI, many IP workflows still  operate  on outdated assumptions. The focus  remains  on generating comprehensive result sets, relying on classifications, and conducting manual-heavy reviews. However, these approaches often  fail to  capture the full scope of innovation and evolving risk.    Patent analysis today requires more than completeness. It requires context, prioritization, and continuous updates. Keyword searches alone cannot capture how inventions are described across  jurisdictions . Classification systems  lag behind  fast-moving technologies. Large datasets, without ranking, create inefficiencies rather than insights.   Modern IP teams are shifting toward intelligence-driven workflows. They integrate AI-assisted discovery, ranking mechanisms, and jurisdiction-aware analysis to focus on what truly matters. Legal status, citation context, and family-level insights ar...

  For years, patent filing decisions followed a predictable formula: file where markets are  large,  enforcement is reliable, and returns justify costs.   That model still  exists  but it no longer defines strategy.   In 2026, geopolitics has become a central force shaping patent behavior. Trade tensions, export controls, and sanctions are influencing not just where companies file, but what they choose to  disclose  and what they deliberately withhold.   Patents are no longer just protection tools. They are also strategic disclosures.   In sensitive sectors like AI, semiconductors, and telecom, companies are shifting from broad coverage to controlled exposure. Core innovations are being  segmented,  filing sequences are carefully timed, and in some cases, trade secrets are preferred over patents to avoid unnecessary risk.   At the same time, enforcement uncertainty is reshaping global priorities. Companies are increas...